Scandinavian Cardiovascular Journal·6 SepA Scandinavian perspective of the projected lifetime cost-effectiveness of rivaroxaban plus aspirin in the COMPASS trialComputational studyInterventionsPaper
Heart·17 AugNT-proBNP in relation to clinical characteristics and cardiovascular outcomes in non-anticoagulated patients with atrial fibrillationTrial in peopleBiomarkersPaper